EUCTR2020-002719-23-GB进行中（未招募）1 期
BT8009-100: Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies - BicycleTx BT8009-100
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 146
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. At least 18 years old at the time informed consent is given.
- •2. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
- •3. Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- •4. Acceptable organ function, as evidenced by the following laboratory data:
- •a) Renal function: creatinine clearance of =50 mL/min by the Cockcroft-Gault equation or equivalent.
- •b) Total bilirubin =1.5 × ULN (upper limit of normal)
- •c) Serum albumin =2.5 g/dL
- •d) Aspartate aminotransferase (AST) =2.5 × ULN or =5 × ULN in the presence of liver metastases
- •e) Alanine aminotransferase (ALT) =2.5 × ULN or =5 × ULN in the presence of liver metastases
- •f) International normal ratio (INR) <1.3 or = institutional ULN
- •5. Acceptable hematologic function (no red blood cell or platelet transfusions or growth factors are allowed within 4 weeks of the first dose of BT8009):
- •a) Hemoglobin =9 g/dL
- •b) Absolute neutrophil count (ANC) =1500 cells/mm³
- •c) Platelet count =75,000 cells/mm³
- •6. Negative pregnancy test for women of childbearing potential (WOCBP) (negative serum test at screening and negative urine or serum test within 3 days prior to the first dose of BT8009. Male patients with female partners of childbearing potential and female patients of childbearing potential are required to follow highly effective contraception (oral and hormonal contraceptives allowed) at least as conservative as Clinical Trial Facilitation Group (CTFG) recommendations for less than 1% failure rate during their participation in the study and for 6 months following last dose of study drug. Male patients must also refrain from donating sperm during their participation in the study and for 6 months following last dose of study drug and women must not breastfeed during that time or donate eggs.
- •7. Availability of archived tumor samples within 12 months prior to the date of the first dose of BT8009 or willingness to provide fresh tumor biopsy during screening.
- •8. Life expectancy =12 weeks after the start of BT8009 treatment according to Investigator's judgment.
- •Additional Inclusion Criteria for Part A
- •9. Patients with advanced, histologically confirmed malignant solid tumors as follows: a) urothelial (transitional cell) carcinoma naïve to Nectin-4 directed therapies; or b) having tumor tissue (fresh biopsy or on archived sample less than 12 months old without intervening anti-cancer therapies) testing positive for Nectin-4 expression; or c) solid tumors known to be historically associated with Nectin-4 as follows: pancreatic, TNBC, NSCLC, gastric, esophageal or ovarian.
- •Exceptions: single-subject accelerated cohorts may enroll patients with advanced solid tumors non-restricted to the above definitions, unless the Safety Review Committee views otherwise. All patients must have disease that recurred after or refractory to previous therapy including appropriate targeted therapies, for example EGFR or ALK therapies for relevant oncogene driver NSCLC patients, and are candidates for a Phase I study due to lack of approved or standard options for treatment.
- •Additional Inclusion Criteria for Parts B-1 and B-2 Nectin-4 basket monotherapy and combination cohorts
- •10. Patients with solid tumor metastatic recurrent disease confirmed to express Nectin-4 on fresh biopsy or archived tissue (<12 months old and with no intervening anti-cancer therapies) are eligible and must have exhausted all standard treatment options, including
排除标准
- •Patients who meet any of the following criteria will be excluded:
- •1. Chemotherapy treatments within 14 days prior to first dose of study treatment.
- •2. Other anticancer treatments within 28 days or 5 half-lives, whichever is shorter. Prior toxicities must have resolved to Grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 (except alopecia which must be no greater than Grade 2).
- •3. Experimental treatments within 4 weeks of first dose of BT8009.
- •4. Prior treatment with Nectin-4 targeted therapy.
- •5. Current treatment with strong inhibitors or strong inducers of CYP3A4 or strong inhibitors of P-gp including herbal or food based.
- •6. Known sensitivity to any of the ingredients of the investigational product or monomethyl auristatin E (MMAE).
- •7. Weight >100 kg or BSA >2.21 m² (representing human 100 kg equivalent for height of 175 cm).
- •8. Conditions related to or that may confound monitoring for dry eye, corneal opacities or keratitis); skin conditions related to or that may confound monitoring for rash, life-threatening illness, active uncontrolled infection or organ system dysfunction, or other reasons which in the Investigator opinion could compromise the patient’s safety, or interfere with or compromise the integrity of the study.
- •9. Clinically relevant troponin elevation
- •10. Uncontrolled diabetes defined as HbA1c =8%
- •11. Major surgery <4 weeks of first dose of BT8009
- •12. Receipt of live vaccine <30 days of study treatment
- •13. Uncontrolled, symptomatic brain metastases
- •14. Patients with uncontrolled hypertension (systolic BP =160 mm Hg or diastolic BP =100 mm Hg) prior to first dose of BT8009
- •15. History or current evidence of any condition, therapy or laboratory abnormality that might confound the results of the study, interfere with the patient’s participation, or is not in the best interest of the patient.
- •16. HIV or acquired immune deficiency syndrome (AIDS)
- •17. Patients with a positive hepatitis B surface antigen and/or anti-hepatitis B core antibody. Patients with a negative polymerase chain reaction (PCR) assay are permitted with appropriate antiviral therapy
- •18. Active hepatitis C infection with positive viral load. Patients who have been treated for hepatitis C infection can be included if they have documented sustained virologic response of =12 weeks.
- •19. History of another malignancy within 3 years before the first dose of BT8009, or any evidence of residual disease from a previously diagnosed malignancy
- •20. Systemic IV anti-infective treatment, or fever within 14 days prior to first dose of BT8009
- •21. Suspicion of relevant and recent systemic viral syndrome or need for quarantine/isolation that is not resolved in the opinion of the investigator
- •22. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures
- •Additional Exclusion Criteria for Part A-2 and B-2 Nivolumab Combination Cohorts
- •23. Prior intolerance to immune checkpoint inhibitor
- •24. Known hypersensitivity to checkpoint inhibitor therapy
- •25. Prior organ transplant (including allogeneic)
- •27. Diagnosis of clinically relevant immunodeficiency
- •28. Active systemic infection requiring therapy
- •29. More than 10 mg daily prednisone equivalent or other strong immunosuppressant
- •30. History of autoimmune disease except type I DM well contained on insulin, alopecia or vitiligo
- •31. History of interstitial lung disease
研究者
相似试验
进行中（未招募）
1 期
Study of IMG-007 in Participants with Moderate to Severe Atopic DermatitisAtopic dermatitisCTIS2023-505735-13-01Inmagene LLC55
进行中（未招募）
1 期
A Study of Oleclumab (MEDI9447) with or without Durvalumab Combined with Chemotherapy in Subjects with Pancreatic CancerPancreatic Ductal AdenocarcinomaMedDRA version: 20.0Level: LLTClassification code 10051971Term: Pancreatic adenocarcinomaSystem Organ Class: 100000004864EUCTR2018-001028-21-ESMedImmune, LLC204
进行中（未招募）
1 期
A Study of Oleclumab (MEDI9447) with or without Durvalumab Combined with Chemotherapy in Subjects with Pancreatic CancerEUCTR2018-001028-21-NOMedImmune, LLC195
已完成
不适用
A Phase 1b Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GS-9820 Monotherapy and Combination Therapy in Subjects with Lymphoid Malignancieson-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, indolent Hodgkin's LymphomaB-cell related malignancy10025319LymphomaNL-OMON39586Gilead Sciences40
进行中（未招募）
不适用
Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With NeutropeniaTreatment and prophylaxis of invasive fungal infectionsoropharyngeal candidiasis (OPC) and refractory OPC.MedDRA version: 17.1Level: PTClassification code 10050346Term: Oropharyngeal candidiasisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2007-004645-15-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.108